(Q53134485)

English

RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.

scientific article published on 22 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yong Park

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Dae S Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Kyong H Park

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Seung-Kuk Baek

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Soon Y Kwon

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Sang W Shin

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Kwang Y Jung

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Chul Y Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Yeol H Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Nam J Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Jun S Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

In S Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

publication date

22 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

35

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

673-682

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Prediction of cancer incidence and mortality in Korea, 2011.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.

1 reference

https://api.crossref.org/works/10.1159%2F000343636

21 January 2018

Identifiers

10.1159/000343636

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23147544

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53134485&oldid=1577705361"